Litcius/Paper detail

<i>Scutellaria baicalensis</i> extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease <i>in vitro</i>

Hongbo Liu, Fei Ye, Qi Sun, Hao Liang, Chunmei Li, Siyang Li, Roujian Lu, Baoying Huang, Wenjie Tan, Luhua Lai

2021Journal of Enzyme Inhibition and Medicinal Chemistry311 citationsDOIOpen Access PDF

Abstract

COVID-19 has become a global pandemic and there is an urgent call for developing drugs against the virus (SARS-CoV-2). The 3C-like protease (3CLpro) of SARS-CoV-2 is a preferred target for broad spectrum anti-coronavirus drug discovery. We studied the anti-SARS-CoV-2 activity of S. baicalensis and its ingredients. We found that the ethanol extract of S. baicalensis and its major component, baicalein, inhibit SARS-CoV-2 3CLpro activity in vitro with IC50’s of 8.52 µg/ml and 0.39 µM, respectively. Both of them inhibit the replication of SARS-CoV-2 in Vero cells with EC50’s of 0.74 µg/ml and 2.9 µM, respectively. While baicalein is mainly active at the viral post-entry stage, the ethanol extract also inhibits viral entry. We further identified four baicalein analogues from other herbs that inhibit SARS-CoV-2 3CLpro activity at µM concentration. All the active compounds and the S. baicalensis extract also inhibit the SARS-CoV 3CLpro, demonstrating their potential as broad-spectrum anti-coronavirus drugs.

Topics & Concepts

BaicaleinScutellaria baicalensisVero cellChemistryProteaseIn vitroCoronavirusViral replicationIC50PharmacologyEC50VirologyVirusEnzymeBiochemistryBiologyCoronavirus disease 2019 (COVID-19)MedicineTraditional Chinese medicineInfectious disease (medical specialty)DiseaseAlternative medicinePathologyFlavonoids in Medical ResearchComputational Drug Discovery MethodsSARS-CoV-2 and COVID-19 Research